NWRD06 DNA Plasmid for HCC After Curative Resection.

This study is testing NWRD06, a DNA-based vaccine-like treatment, in people with liver cancer (hepatocellular carcinoma, or HCC) who have already had curative surgery or ablation to remove the cancer. The goal is to reduce the chance of the cancer coming back. **You may be eligible if...** - You are 18–65 years old - You have been diagnosed with liver cancer confirmed by biopsy - Your tumor expresses a protein called GPC3 (confirmed by a tissue test) - You have had curative surgery or ablation within the past 12 weeks, with no remaining cancer on imaging - Your liver function is preserved (Child-Pugh A or B with score ≤7) - Your blood counts, liver, and kidney function meet the required thresholds **You may NOT be eligible if...** - Your cancer has spread to lymph nodes or other organs - You had incomplete tumor removal or your surgical margin was not clear - You have major blood vessel invasion (tumor thrombus in the main portal vein or hepatic veins) - You have already received cancer treatment Talk to your doctor to see if this trial is right for you.